In today’s briefing:
- Mayne Pharma (MYX AU): Entering Uncharted Territory as the Scheme Vote Passes
- Mayne Pharma (MYX AU): The Vote Gets Up. Now What?
- Business Breakdown: Zydus Lifesciences ~ Bet on R&D and New Launches to Fill the Revenue Gap
- Telix Pharmaceuticals (TLX AU): New Product Launch In US; More to Follow; Illuccix on Strong Footing
- Medtide (泰德医药) Pre-IPO: Mind the CG Risk
- Caris Life Sciences, Inc. (CAI): AI Cancer TechBio Company Surges Six Points at Open
- Pre-IPO Saint Bella (PHIP Updates) – Some Points Worth the Attention
- MIRA: Journal Acceptance Adds Validation
- Ainos, Inc: Positive Momentum Heading into 2H25
- Swedish Orphan Biovitrum AB: Strategic Launches
Mayne Pharma (MYX AU): Entering Uncharted Territory as the Scheme Vote Passes
- To no one’s surprise, the Mayne Pharma (MYX AU) scheme vote comfortably passed. The scheme remains conditional on FIRB approval and no material adverse change (which Cosette alleges).
- The Mayne/Cosette court case wades into uncharted territory as it brings many firsts, such as the first MAC-related dispute to be heard in Australian courts with a qualified MAC threshold.
- While Western case law burdens the buyer with establishing a MAC breach, it is unclear whether Mayne will get a favourable ruling, as Cosette could have a case. Tread carefully.
Mayne Pharma (MYX AU): The Vote Gets Up. Now What?
- I have no clue. Given this is unchartered territory, in Australia, I don’t believe anyone has a perfect handle on the situation
- What do we know? The Second Court meeting has been pushed out to the 18th September from 20th June initially, to “enable the dispute with Cosette“.
- This date may be further delayed as a court hearing will commence on the 9th September to hear the validity of Cosette’s termination notice.
Business Breakdown: Zydus Lifesciences ~ Bet on R&D and New Launches to Fill the Revenue Gap
- Zydus Lifesciences Ltd (ZYDUSLIF IN) is a leading global healthcare company specializing in generic drugs, biosimilars, and innovative therapies across multiple therapeutic areas.
- While the Revlimid slowdown risk looms, Zydus aims to offset this with a strong pipeline of new product launches and R&D innovations.
- Its secondary sales have consistently outpaced market growth, driven by strong performances in chronic and specialty products.
Telix Pharmaceuticals (TLX AU): New Product Launch In US; More to Follow; Illuccix on Strong Footing
- Telix Pharmaceuticals (TLX AU) has launched next-generation prostate cancer imaging agent, Gozellix in the U.S. With two FDA-approved commercial products, current U.S. addressable market opportunity is $2.5B+.
- The FDA is expected to communicate its decision regarding the approval of Zircaix, kidney cancer imaging candidate, on August 27. Telix estimates initial U.S. market opportunity for Zircaix is $500M+.
- Illuccix continued its momentum through gaining market share and maintaining price stability in a competitive landscape. In 1Q25, Illuccix revenue increased 35% YoY and 9% QoQ to $151M.
Medtide (泰德医药) Pre-IPO: Mind the CG Risk
- Medtide, a Chinese headquartered CDMO company, is seeking to raise at least USD 100m via a Hong Kong listing. The deal sponsors are MS and CITIC.
- In this note, we take a quick look at the company’s fundamentals.
- We highlighted its corporate governance risk despite its decent financials as compared to larger players.
Caris Life Sciences, Inc. (CAI): AI Cancer TechBio Company Surges Six Points at Open
- The next-generation AI TechBio company priced a full size deal of 23.5mm shares at $21.00 and opened at $27.00 for a gain of 28.6% at first trade.
- It was easy for IPO investors to wrap their heads around this company. Caris generates billions of data points and uses AI to customize immunotherapy for individuals.
- Looking ahead, it is our opinion that this “could” be a company that investors tuck away in their portfolio for a long time.
Pre-IPO Saint Bella (PHIP Updates) – Some Points Worth the Attention
- The mismatch between supply and demand in the postpartum center market has become apparent, coupled with consumption downgrades in high-end market, which has limited the growth potential of SAINT BELLA.
- The gross margin of SAINT BELLA that focuses on high-end postpartum services is surprisingly lower than that of traditional general hospital business, indicating that the Company’s profitability is disappointing.
- SAINT BELLA attempts to attract capital through the story of “high-end services+overseas expansion”,but its model has contradictions.The essence of IPO is “a last ditch effort” for capital to cash out.
MIRA: Journal Acceptance Adds Validation
- MIRA Pharmaceuticals(MIRA) Company Sponsored Research Report
Ainos, Inc: Positive Momentum Heading into 2H25
- Mid-year progress report and remaining milestones for 2025.
- Ainos provided a mid-year update, reviewing 1H25 achievements and laying out the 2H25 roadmap to deliver continued progress in multiple AI Nose programs and Veldona clinical development.
- AI Nose has partnered projects in healthcare, robotics, and industrials, all ready for pilot launches in 2H25.
Swedish Orphan Biovitrum AB: Strategic Launches
- Swedish Orphan Biovitrum AB (Sobi), a pharmaceutical company specializing in the treatment of rare diseases, presented its Q1 2025 results.
- The financial metrics and qualitative insights from the earnings call offer a nuanced view of the company’s operations and strategic direction.
- The first quarter of 2025 demonstrated a mixed performance for Sobi.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
